A07006 Summary:

BILL NOA07006
 
SAME ASSAME AS S05629
 
SPONSORGottfried
 
COSPNSRKearns, Zebrowski, Ortiz, Mosley, Lavine, Hunter, Cook, Hevesi, D'Urso, Skoufis, Simon, Glick, McDonald, Miller ML, Sepulveda, Walter, Peoples-Stokes, Hooper, Galef, Richardson, Moya, Carroll, Blake, Lupardo, Brindisi, Steck, Raia, Wallace, Morelle, Abinanti, Wright, Kolb, Walker
 
MLTSPNSRCahill, Dinowitz, Lentol, McDonough, McLaughlin, Morinello, Rozic
 
Amd 3360, Pub Health L
 
Includes post-traumatic stress disorder as a condition permitting the use of medical marihuana.
Go to top    

A07006 Actions:

BILL NOA07006
 
03/29/2017referred to health
04/25/2017reported
04/27/2017advanced to third reading cal.239
05/02/2017passed assembly
05/02/2017delivered to senate
05/02/2017REFERRED TO HEALTH
06/20/2017SUBSTITUTED FOR S5629
06/20/20173RD READING CAL.903
06/20/2017PASSED SENATE
06/20/2017RETURNED TO ASSEMBLY
11/10/2017delivered to governor
11/11/2017signed chap.403
Go to top

A07006 Committee Votes:

HEALTH Chair:Gottfried DATE:04/25/2017AYE/NAY:26/0 Action: Favorable
GottfriedAyeRaiaAye
SchimmingerAyeMcDonoughAye
GalefAyeRaAye
DinowitzAyeWalterAye
CahillAyeGarbarinoAye
PaulinAyeByrneAye
CymbrowitzAyeNorrisAye
GuntherAye
RosenthalAye
HevesiAye
LavineAye
TitoneAye
MayerAye
JaffeeAye
SteckAye
AbinantiAye
BraunsteinAye
KimAye
SolagesAye

Go to top

A07006 Floor Votes:

DATE:05/02/2017Assembly Vote  YEA/NAY: 131/8
AbbateYCrouchYGoodellNOLiftonYO'DonnellYSimanowitzY
AbinantiYCurranNOGottfriedYLopezYOrtizYSimonY
ArroyoYCusickYGrafNOLupardoYOtisYSimotasER
AubryYCymbrowitzYGuntherYLupinacciERPalmesanoERSkartadosY
BarclayYDavilaYHarrisYMageeYPalumboYSkoufisY
BarnwellYDe La RosaYHawleyNOMagnarelliYPaulinYSolagesY
BarrettYDenDekkerYHevesiERMalliotakisYPeoples-StokesERStecY
BarronYDickensYHikindYMayerYPerryYSteckY
BenedettoYDilanYHooperYMcDonaldYPheffer AmatoYStirpeER
BichotteYDinowitzYHunterYMcDonoughYPichardoYThieleY
BlakeYDiPietroERHyndmanYMcKevittYPretlowYTitoneY
BlankenbushYD'UrsoYJaffeeYMcLaughlinYQuartYTitusY
BrabenecNOEnglebrightYJean-PierreYMill B YRaYVanelY
BraunsteinYErrigoYJenneYMill MGYRaiaYWalkerY
BrindisiYFahyYJohnsYMill MLYRamosYWallaceY
BronsonYFarrellYJonesYMontesanoNORichardsonYWalshY
BuchwaldYFinchERJoynerYMorelleYRiveraYWalterY
ButlerYFitzpatrickNOKavanaghYMorinelloYRodriguezYWeinsteinY
ByrneYFriendNOKearnsYMosleyYRosenthalYWeprinY
CahillYGalefYKimYMoyaYRozicYWilliamsY
CarrollYGanttERKolbYMurrayYRyanYWoernerY
CastorinaYGarbarinoYLalorYNiouYSantabarbaraYWrightY
ColtonYGiglioERLavineYNolanYSchimmingerYZebrowskiY
CookYGjonajYLawrenceYNorrisYSeawrightYMr SpkrY
CrespoYGlickYLentolYOaksYSepulvedaY

Go to top

A07006 Memo:

NEW YORK STATE ASSEMBLY
MEMORANDUM IN SUPPORT OF LEGISLATION
submitted in accordance with Assembly Rule III, Sec 1(f)
 
BILL NUMBER: A7006
 
SPONSOR: Gottfried (MS)
  TITLE OF BILL: An act to amend the public health law, in relation to conditions permitting the use of medical marihuana   PURPOSE OR GENERAL IDEA OF BILL: This bill would make post-traumatic stress disorder (PTSD) an eligible condition under the state medical marijuana law.   SUMMARY OF PROVISIONS: Section 1 of this bill amends section 3360 of the Public Health Law, to add post traumatic stress disorder to the list of conditions for which medical marijuana may be used. Section 2 of this bill provides that this act shall take effect imme- diately.   EXISTING LAW: The Public Health Law specifies ten medical conditions that are eligible for use of medical marijuana and chronic pain has been added by action of the Health Commissioner. PTSD is not among those conditions.   JUSTIFICATION: Post-traumatic stress disorder (PTSD), first defined in 1980, is a seri- ous condition that involves a person developing symptoms - such as anger, flashbacks, nightmares, night sweats, numbing, insomnia, and avoidance - after experiencing a traumatic stressor. Many patients find the available pharmaceutical options dangerous or ineffective, and thou- sands of them have turned to medical marijuana for relief. States are increasingly adding PTSD to their lists of qualifying conditions for medical marijuana. PTSD afflicts numerous patient groups. While the public typically asso- ciates PTSD with military veterans, PTSD is also found among survivors of domestic violence, rape, violent crime, accidents, and among police and fire fighters. Women are twice as likely as men to experience PTSD. PTSD results from an endocannabinoid deficiency. The endocannabinoid system is part of the brain and nervous system involved with appetite, pain-sensation, mood, and memory. With PTSD, the body stops producing enough endocannabinoids to fill receptor sites. This is where the canna- binoids found in marijuana play a therapeutic role. Of the 28 states with medical marijuana programs, 23 cover patients with PTSD. Six of those states collect patient use data. Extrapolating from the relative number of PTSD patients in those six states, approximately 19,000 patients with PTSD in New York could benefit from the use of medical marijuana. Some argue that treatment of PTSD with medical marijuana is not based on double-blind clinical studies proving its efficacy. However, most of the drugs commonly used to treat PTSD also lack clinical proof of their efficacy. Only two drugs have been approved by the FDA for the treatment of PTSD: sertraline (Zoloft), and paroxetine (Paxil). Unlike medical marijuana, both of these drugs have serious side effects, including the risk of suicide, weight gain, and the onset of diabetes. Every other drug used in the treatment of PTSD is prescribed "off label," which means they were not approved by the FDA for the treatment of PTSD. Many of these drugs, which include benzodiazepines, antipsychotics, and mood stabilizers, are even more dangerous and addictive than Zoloft and Paxil. Indeed, the Army Surgeon General issued a warning against the use of antipsychotics for veterans with PTSD in 2012. While available research about medical marijuana for PTSD is limited-be- cause of federal obstacles to conducting such research-the research that does exist supports the use. For example, a Canadian study involving naboline - a prescription drug made of a synthetic cannabinoid (compo- nent of marijuana) reported that, "The majority of patients (72%) receiving naboline experienced either cessation of nightmares or a significant reduction in nightmare intensity. Subjective improvement in sleep time, the quality of sleep, and the reduction of day-time flash- backs and nightsweats were also noted by some patients." In New Mexico, a 2014 study of 80 patients who administered medical marijuana for PTSD, pursuant to state law, found "greater than 75% reduction in CAPS (Clinician Administered Post-traumatic Scale) symptom scores were reported when patients were using cannabis than when they were not... There is extensive evidence that cannabinoids may facilitate extinction of aversive memories." They also found a 77% reduction in suicidal thoughts, and a 50% reduction in the use of medications. The New Mexico study also reported that not a single adverse event occurred among over 3,350 patients with PTSD using medical marijuana that they were tracking.   PRIOR LEGISLATIVE HISTORY: New bill.   FISCAL IMPLICATIONS: The State of New York and certain counties will realize additional tax revenue from the sale of medical marijuana to patients with PTSD.   EFFECTIVE DATE: Immediately
Go to top

A07006 Text:



 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                          7006
 
                               2017-2018 Regular Sessions
 
                   IN ASSEMBLY
 
                                     March 29, 2017
                                       ___________
 
        Introduced  by  M.  of  A.  GOTTFRIED, KEARNS, ZEBROWSKI, ORTIZ, MOSLEY,
          LAVINE, HUNTER, COOK, HEVESI, D'URSO, SKOUFIS, SIMON, GLICK, McDONALD,
          M. L. MILLER, SEPULVEDA, WALTER, PEOPLES-STOKES, HOOPER, GALEF,  RICH-
          ARDSON,  MOYA, CARROLL, BLAKE, LUPARDO, BRINDISI -- Multi-Sponsored by
          -- M. of A.  CAHILL, DINOWITZ, FARRELL, LENTOL, McDONOUGH, McLAUGHLIN,
          MORINELLO, ROZIC -- read once and referred to the Committee on Health
 
        AN ACT to amend the public health law, in relation to conditions permit-
          ting the use of medical marihuana
 
          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:
 
     1    Section  1.  Paragraph  (a)  of  subdivision  7 of section 3360 of the
     2  public health law, as added by chapter  90  of  the  laws  of  2014,  is
     3  amended to read as follows:
     4    (a) "Serious condition" means:
     5    (i)  having one of the following severe debilitating or life-threaten-
     6  ing conditions: cancer, positive status for human immunodeficiency virus
     7  or acquired immune deficiency syndrome, amyotrophic  lateral  sclerosis,
     8  Parkinson's disease, multiple sclerosis, damage to the nervous tissue of
     9  the  spinal  cord  with objective neurological indication of intractable
    10  spasticity,  epilepsy,   inflammatory   bowel   disease,   neuropathies,
    11  Huntington's disease, post-traumatic stress disorder, or as added by the
    12  commissioner; and
    13    (ii) any of the following conditions where it is clinically associated
    14  with,  or  a  complication  of,  a condition under this paragraph or its
    15  treatment: cachexia or wasting syndrome; severe or chronic pain;  severe
    16  nausea; seizures; severe or persistent muscle spasms; or such conditions
    17  as are added by the commissioner.
    18    §  2. This act shall take effect immediately; provided that the amend-
    19  ments to title 5-A of article 33  of  the  public  health  law  made  by
    20  section  one  of  this act shall not affect the repeal of such title and
    21  shall be deemed repealed therewith.
 
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD10804-01-7
Go to top